Soligenix
Princeton, United StatesFounded 1987Industry
Soligenix develops biodefense vaccines and therapeutics including for radiation injury. CBRNE-relevant work is a notable product line according to its website.
What it does
Threats covered
Categories
Profile
Soligenix is a Princeton, New Jersey biopharmaceutical company incorporated in 1987 and listed on Nasdaq under SNGX. Its Public Health Solutions programme includes RiVax, a ricin toxin vaccine candidate that has completed phase 1 trials, and ThermoVax, a heat stabilisation platform intended to remove the need for vaccine cold chains, which remains preclinical.
More profile
The company says these programmes have had government grant and contract support from NIAID, BARDA and the Defense Threat Reduction Agency, and that it continues to seek additional funding. Its annual report for 2025 and its second quarter 2026 results are public.
Most of its business is in rare disease and oncology.
Ownership
Publicly listed on Nasdaq (SNGX)
Parent: none (publicly listed) (checked)
Sources (4)
- https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/sngx-20251231x10k.htm
- https://www.publicnow.com/view/C37DEEA20FBF5792D86C47FC4BB3DDBE9947E49A
- https://ir.soligenix.com/2026-08-07-Soligenix-Announces-Recent-Updates-and-Second-Quarter-2026-Financial-Results
- https://www.sec.gov/Archives/edgar/data/812796/000110465926037730/R9.htm
Not verified or not found
- Contract and grant values: not read.
- Whether older anthrax, smallpox or Ebola programmes remain active: not read.
Questions
What does Soligenix do?
Soligenix develops biodefense vaccines and therapeutics including for radiation injury. CBRNE-relevant work is a notable product line according to its website.
Where is Soligenix based?
HQ (as found): Princeton. HQ country: US.
Who owns Soligenix?
Publicly listed on Nasdaq (SNGX). Parent: none (publicly listed) (checked)
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction